Fractalkine/CX3CL1 induced intercellular adhesion molecule-1-dependent tumor metastasis through the CX3CR1/PI3K/Akt/NF-κB pathway in human osteosarcoma

被引:35
|
作者
Liu, Ju-Fang [1 ]
Tsao, Ya-Ting [2 ]
Hou, Chun-Han [2 ]
机构
[1] Shin Kong Wu Ho Su Mem Hosp, Cent Lab, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Orthoped Surg, Taipei, Taiwan
关键词
fractalkine; osteosarcoma; metastasis; cell migration; ICAM-1; PROSTATE-CANCER CELLS; SMOOTH-MUSCLE-CELLS; ICAM-1; EXPRESSION; TNF-ALPHA; HEPATOCELLULAR-CARCINOMA; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; CHEMOKINE CX3CL1; RECEPTOR CX3CR1; GASTRIC-CANCER;
D O I
10.18632/oncotarget.11250
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Osteosarcoma is the most common primary bone tumor in children and teens. The exact molecular mechanism underlying osteosarcoma progression still remains unclear. The CX3CL1/fractalkine has been implicated in various tumors but not in osteosarcoma. This study is the first to show that fractalkine promotes osteosarcoma metastasis by promoting cell migration. Fractalkine expression was higher in osteosarcoma cell lines than in normal osteoblasts. Fractalkine induced cell migration by upregulating intercellular adhesion molecule-1 (ICAM-1) expression via CX3CR1/PI3K/Akt/NF-kappa B pathway in human osteosarcoma cells. Knockdown of fractalkine expression markedly inhibited cell migration and lung metastasis in osteosarcoma. Finally, we showed a clinical correlation between CX3CL1 expression and ICAM-1 expression as well as tumor stage in human osteosarcoma tissues. In conclusion, our results indicate that fractalkine promotes cell migration and metastasis of osteosarcoma by upregulating ICAM-1 expression. Thus, fractalkine could serve a novel therapeutic target for preventing osteosarcoma metastasis.
引用
收藏
页码:54136 / 54148
页数:13
相关论文
共 50 条
  • [2] Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway
    Stavros Apostolakis
    Demetrios Spandidos
    [J]. Acta Pharmacologica Sinica, 2013, 34 : 1251 - 1256
  • [3] Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway
    Apostolakis, Stavros
    Spandidos, Demetrios
    [J]. ACTA PHARMACOLOGICA SINICA, 2013, 34 (10) : 1251 - 1256
  • [4] Role of fractalkine/CX3CL1 and its receptor CX3CR1 in allergic diseases
    Julia, Valerie
    Staumont-Salle, Delphine
    Dombrowicz, David
    [J]. M S-MEDECINE SCIENCES, 2016, 32 (03): : 260 - 266
  • [5] Therapeutic intervention of inflammatory/ immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway
    Imai T.
    Yasuda N.
    [J]. Inflammation and Regeneration, 36 (1)
  • [6] Modulating neurotoxicity through CX3CL1/CX3CR1 signaling
    Limatola, Cristina
    Ransohoff, Richard M.
    [J]. FRONTIERS IN CELLULAR NEUROSCIENCE, 2014, 8
  • [7] Relevance of the CX3CL1/fractalkine-CX3CR1 pathway in vasculitis and vasculopathy
    Kasama, Tsuyoshi
    Wakabayashi, Kuninobu
    Sato, Michihito
    Takahashi, Ryo
    Isozaki, Takeo
    [J]. TRANSLATIONAL RESEARCH, 2010, 155 (01) : 20 - 26
  • [8] Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis
    Hasegawa, M
    Sato, S
    Echigo, T
    Hamaguchi, Y
    Yasui, M
    Takehara, K
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (01) : 21 - 28
  • [9] Regulation of microglia neurotoxicity by CX3CR1 and CX3CL1
    Cardona, AE
    Huang, DR
    Sasse, ME
    Kidd, G
    Lira, S
    Cook, D
    Jung, S
    Littman, D
    Ransohoff, R
    [J]. FASEB JOURNAL, 2005, 19 (04): : A940 - A940
  • [10] Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in periodontal diseased tissue
    Hosokawa, Y
    Nakanishi, T
    Yamaguchi, D
    Nakae, H
    Matsuo, T
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2005, 139 (03): : 506 - 512